Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers.
TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers.
Journal: Cancer discovery
Published: January 12, 2026
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9.
Journal: Journal of medicinal chemistry
Published: November 24, 2025
Prospects for combining targeted and conventional cancer therapy with immunotherapy.
Journal: Nature reviews. Cancer
Published: March 25, 2017
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 25, 2016
Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Journal: Science (New York, N.Y.)
Published: November 15, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Journal: Cancer discovery
Published: March 29, 2014
Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026